merckdecisionanalysis内容摘要：
M. Therefore, they should be willing to pay anything less than this amount. 4. What is the expected value of the licensing arrangement to LAB? Assume a 5% royalty fee on any cash flows that Merck receives from Davanrik after a successful launch and that the present value of benefits are of royalties. Phase I(100% chance of occurring): $5 million Phase II(60%): $ million Phase III depression(10%): $20 million Phase III weight loss(15%): $10 million Phase III both(5%): $40 million Depression suc。阅读剩余 0%
本站所有文章资讯、展示的图片素材等内容均为注册用户上传(部分报媒/平媒内容转载自网络合作媒体)，仅供学习参考。
用户通过本站上传、发布的任何内容的知识产权归属用户或原始著作权人所有。如有侵犯您的版权，请联系我们反馈本站将在三个工作日内改正。